Fundamentals Hub
ENZN ENZON PHARMACEUTICALS, INC.
ENZN financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 17 annual and 0 of 64 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$4.92M (Jun 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(630) 874-0700
EIN
222372868
Headquarters
LOMBARD, IL, 60148
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
ENZON PHARMACEUTICALS, INC. (2016–2026)
· ENZON PHARMACEUTICALS INC (2006–2016)
· ENZON PHARMACEUTICALS INC (2002–2006)
· ENZON PHARMACEUTICAL INC (2002–2002)
· ENZON INC (1995–2002)
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$18.67M
Total Assets
$424.48M
Total Equity
$185.21M
Total Debt
$129.40M
Free Cash Flow
-
Ratios
Return on Equity
10.1%
Return on Assets
4.4%
Current Ratio
1.84x
Debt / Equity
0.7x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | - | $26.00K | - |
| OPERATING EXPENSES | |||
| Operating Income | $-5.31M | $-1.33M | $-1.04M |
| NON-OPERATING INCOME / EXPENSE | |||
| Pretax Income | $-3.39M | $1.13M | $1.22M |
| Income Tax | $19.00K | $347.00K | $-156.00K |
| Net Income | $-3.41M | $778.00K | $1.37M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.07 | $-0.01 | $0.00 |
| Diluted Shares | 74.22M | 74.22M | 74.22M |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $42.57M | $46.86M | $47.01M |
| Other Current Assets | $239.00K | $293.00K | $331.00K |
| Current Assets | $42.81M | $47.15M | $47.34M |
| Noncurrent Assets | $0 | $17.00K | $359.00K |
| Total Assets | $42.81M | $47.17M | $47.70M |
| LIABILITIES | |||
| Accounts Payable | $331.00K | $331.00K | $331.00K |
| Other Current Liabilities | $9.00K | $5.00K | $16.00K |
| Current Liabilities | $731.00K | $1.68M | $1.71M |
| EQUITY | |||
| Common Stock | $742.00K | $742.00K | $742.00K |
| Additional Paid-in Capital | $70.03M | $72.16M | $73.43M |
| Retained Earnings | $-73.30M | $-69.89M | $-70.67M |
| Total Equity | $-2.53M | $3.01M | $-3.51M |
| Total Liabilities & Equity | $42.81M | $47.17M | $47.70M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 74.21M | 74.21M | 74.21M |
| Check: A − (L + E + NCI) | $45.34M | $44.16M | $51.21M |
| Cash Flow Statement | |||
| Cash from Operations | $-3.01M | $1.12M | $1.31M |
| Capital Expenditures | - | - | - |
| Cash from Investing | - | - | - |
| Cash from Financing | $-1.28M | $-1.28M | $-1.28M |
| Free Cash Flow | - | - | - |
| Beginning Cash (CFS) | $46.86M | $47.01M | - |
| Net Change in Cash | - | - | - |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | - | - | - |
| Cash per BS | $42.57M | $46.86M | $47.01M |
| Cash scope difference (CFS − BS) | - | - | - |
| Cash per CFS | $42.57M | $46.86M | $47.01M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is ENZON PHARMACEUTICALS, INC. profitable?
Yes. ENZON PHARMACEUTICALS, INC. reported $18.67M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.
What is ENZON PHARMACEUTICALS, INC.'s debt level?
ENZON PHARMACEUTICALS, INC. carries $129.40M in total debt as of trailing twelve months. Total shareholders' equity stands at $185.21M.